Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Y. Umeyama
P3.01-76 Clinical Background and Response to Chemotherapy in NSCLC Patients With MET Exon14 Skipping Mutation or High MET Gene Copy Number
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA21.03 Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MET in Gastric Carcinomas: Comparison Between Protein Expression and Gene Copy Number and Impact on Clinical Outcome
British Journal of Cancer
Cancer Research
Oncology
P3.01-44 CYFRA 21-1 as a Predictor to Response to Chemotherapy and Overall Survival in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-51 Outcomes With Systemic Chemotherapy in Advanced NSCLC Patients With Performance Status 2 and Above and Without Driver Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy